Dupixent and vaccines bring Sanofi back to growth by Angus Liu Wednesday, October 31, 2018 Dupixent grew sales by 28% sequentially at constant currencies, to €225 million, and that doesn't even count a recent major approval in asthma.
Bankruptcy looms for bruised Trulance maker Synergy by Angus Liu Friday, October 26, 2018 With its Trulance launch on the skids, Synergy is running out of cash and needs to win new debt terms to avoid bankruptcy.
Alexion crowns myasthenia gravis as best-ever Soliris launch by Angus Liu Wednesday, October 24, 2018 With its new use in gMG, Soliris volume grew 24% year-over-year to a third-quarter haul of $888 million.
FDA hands Novartis a canakinumab rejection by Angus Liu Thursday, October 18, 2018 Novartis is raising its 2018 sales outlook, but canakinumab won’t help it hit the new target—at least not in the cardiovascular sales department.
Roche insists its new drugs will outgrow U.S. biosim erosion by Angus Liu Wednesday, October 17, 2018 Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.
Awaiting Zytiga patent decision, J&J touts pharma growth by Eric Sagonowsky Tuesday, October 16, 2018 J&J could suffer a big patent loss for Zytiga, but even if that happens, the company argues it can grow faster than its peers.
GSK's respiratory franchise takes a big hit with Nucala rebuff by Tracy Staton Monday, September 10, 2018 GSK's Nucala took a big hit Friday when the FDA stiff-armed its hoped-for new approval in COPD, which could have boosted sales significantly.
Shire eyes blockbuster sales with new HAE drug Takhzyro by Carly Helfand Friday, August 24, 2018 Shire got a brand-new approval that could help it dominate the hereditary angioedema market for years—and rack up blockbuster sales in the process.
The top 5 CV drugs from 2017 to 2024 by Angus Liu Friday, August 24, 2018 BMS and Pfizer’s Eliquis and J&J and Bayer’s Xarelto will lead the pack in 2024, followed by Amgen’s Repatha, Novartis’ Entresto and J&J's Uptravi.
FiercePharmaAsia—Lenvima, China’s drug invite, Samsung and more by Angus Liu Friday, August 10, 2018 Lenvima's quarterly sales grow to $106 million; China makes 48-drug list for streamlined review; Samsung commits further investment in biologics.